Synovitis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Mon, 22 Jun 2026 04:02:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Synovitis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Efficacy of efanesoctocog alfa in reducing synovitis in patients with congenital hemophilia A – a multicenter, randomized, open‑label phase 3 trial https://clinicaltrials.eu/trial/efficacy-of-efanesoctocog-alfa-for-reducing-synovitis-in-patients-with-congenital-hemophilia-a/ Wed, 17 Jun 2026 04:03:06 +0000 https://clinicaltrials.eu/trial/efficacy-of-efanesoctocog-alfa-for-reducing-synovitis-in-patients-with-congenital-hemophilia-a/ The study focuses on people born with a blood‑clotting disorder called Congenital hemophilia A, which can cause bleeding into joints and lead to inflammation of the joint lining known as synovitis. The medication being tested is a replacement factor called efanesoctocog alfa, given by intravenous injection to raise the blood’s clotting factor level.

The purpose of the study is to see whether giving a higher amount of this replacement therapy can reduce or eliminate the signs of synovitis over a year. Participants will receive regular infusions of the medicine, will have periodic checks of joint health using ultrasound imaging, and will be followed for about 12 months to record any bleeding events and any side effects.

Throughout the trial, safety will be monitored by recording any adverse events, and the amount of clotting factor in the blood will be measured to understand how long therapeutic levels are maintained. The study will collect information on how often bleeding occurs in joints and the overall number of bleeds, as well as whether the joint inflammation improves.

]]> Study of intra-articular liraglutide (4P004) for patients with knee synovitis and osteoarthritis https://clinicaltrials.eu/trial/study-of-intra-articular-liraglutide-4p004-for-patients-with-knee-synovitis-and-osteoarthritis/ Wed, 29 Apr 2026 15:06:39 +0000 https://clinicaltrials.eu/trial/study-of-intra-articular-liraglutide-4p004-for-patients-with-knee-synovitis-and-osteoarthritis/ This clinical trial investigates a new treatment for patients with knee synovitis and osteoarthritis, conditions that cause pain and inflammation in the knee joint. The study will test a medication called 4P-004, which contains the active substance liraglutide, given through intra-articular injection directly into the knee joint.

The purpose of this research is to determine how well 4P-004 works in reducing knee pain and whether it is safe to use. During the study, participants will receive either 4P-004 or placebo injections. The treatment period lasts 12 weeks, during which participants will have their knee pain and overall condition regularly evaluated.

The medication will be administered as an injection solution, with a maximum daily dose of 2 milligrams. Throughout the study, participants will undergo various assessments to monitor their response to treatment, including evaluations of pain levels during daily activities and overall knee function. The study includes regular check-ups to monitor the participants’ health and safety.

]]> Study on the Safety and Effects of AMB-05X Injections for Patients with Tenosynovial Giant Cell Tumor https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-amb-05x-injections-for-patients-with-tenosynovial-giant-cell-tumor/ Wed, 29 Apr 2026 14:26:38 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-amb-05x-injections-for-patients-with-tenosynovial-giant-cell-tumor/ This clinical trial is focused on studying a condition known as Tenosynovial Giant Cell Tumor (TGCT). TGCT is a type of tumor that affects the joints, causing pain and stiffness. The treatment being tested in this study is called AMB-05X, which is administered as a solution for injection directly into the joint. The purpose of the study is to evaluate the safety and effectiveness of AMB-05X in treating TGCT.

The study is divided into two parts. In the first part, participants will receive treatment with AMB-05X for 24 weeks. During this time, researchers will monitor how well the treatment works and any side effects that may occur. After the initial treatment period, participants may continue into the second part of the study, which involves extended treatment and observation. This part aims to gather more information on the long-term effects of the treatment.

Throughout the study, participants will undergo various assessments, including imaging tests like MRI scans, to measure the size of the tumor and evaluate the response to the treatment. The study will also track changes in joint movement, pain levels, and overall physical function. By participating in this study, researchers hope to gain valuable insights into the potential benefits of AMB-05X for individuals with TGCT.

]]>